. 2010 Jul 1;24(7):421–428. doi: 10.1089/apc.2009.0240

Table 1.

Unadjusted Predictors of Taking HAART 6 months Later Among HIV-Seropositive Injection Drug Users (Logistic General Estimating Equations; INSPIRE Study, 2001–2005)

	Full sample (n = 1,225)			Participants in HIV primary care^# (n = 1,040)
Characteristics	%	Unadjusted Odds Ratio	95% CI	%	Unadjusted Odds Ratio	95% CI
Individual-level factors
Sex: male	62.2	1.13	0.85, 1.51	62.4	1.15	0.85, 1.56
Education: ≤8th grade	14.2	0.57^**	0.38, 0.84	13.8	0.53^**	0.35, 0.80
Race: non-Hispanic Black	75.4	1.11	0.81, 1.53	74.6	1.19	0.85, 1.66
Age, baseline	42.5^a	1.03^**	1.01, 1.05	42.7^a	1.03^*	1.00, 1.05
Drug use, current	74.6	0.63^**	0.53, 0.87	74.7	0.64^**	0.48, 0.85
CD4 count: <350	54.7	1.72^**	1.31, 2.25	56.4	1.61^**	1.21, 2.13
Depression (BSI): mean^b	1.97^a	0.83^*	0.72, 0.97	1.96^a	0.85^*	0.72, 0.99
Positive attitude: health benefits of HAART even if using drugs: strongly agree^c	79.3	1.55^**	1.15, 2.09	79.5	1.53^**	1.11, 2.11
Structural factors
Health care coverage	79.3	3.00^**	2.08, 4.33	83.5	2.64^**	1.75, 3.97
Stable housing	90.7	2.76^**	1.73, 4.43	93.3	2.71^**	1.53, 4.78
Methadone treatment, current	31.7	1.52^*	1.13, 2.04	34.1	1.34⁺	0.99, 1.82
HIV primary care visits: >4 in past 6 months	36.1	2.14^**	1.65, 2.77	42.2	1.67^**	1.28, 2.18
Interpersonal factor
Patient-provider engagement: perfect	—	—	—	36.2	1.42^*	1.08, 1.87
Social Support, emotional and/or instrumental assistance	63.4	1.13	0.88, 1.46	66.4	1.04	0.79, 1.37

^{^#}

At least one visit in the prior 2 years.

^⁺

p < 0.10, *p < 0.05, **p < 0.01, by the Wald statistic.

^{^a}

Mean.

^{^b}

Odds of being on HAART for each additional increase in one unit on scale.

^{^c}

Versus strongly disagree, disagree, or agree.